RarePlex® CTC Assays

Accurate and reproducible CTC detection and phenotyping. Expansive range of biomarkers and indications.

RarePlex assays are designed for detection and phenotyping of CTCs from blood samples



RarePlex kits


3 channels used to detect CTC, 2 channels available for custom biomarkers

Modular RarePlex Developer technology enables flexible and rapid incorporation of custom biomarkers

Rigorously validated for ML-assisted accurate and reproducible rare cell detection and phenotyping

Designed for use with AccuCyte Sample Preparation System, automated stainers, and CyteFinder Instruments

Expansive range of biomarkers and indications

RarePlex CTC assays have been developed for monitoring the therapeutic response of a wide range of biomarkers in multiple indications:

  • Prostate Cancer: AR, ARv7, PSMA, SYP, PSA, Muc1, MAO-A, Muc1
  • Breast Cancer: HER2, ER, PR
  • Immuno-oncology: PD-L1, IRF-1
  • Lung Cancer: EGFR, HER3
  • Melanoma: S-100, Melan-A, NG-2
  • EMT: Vimentin, N-cadherin
  • Proliferation: Ki-67
  • Other: Rad-51, gH2AX, CD11b, CD34, CD146

RarePlex® CTC Assays: Design and Analytical Validation for Circluating Tumor Cells

Presented by Dr. Tad George, Sr. VP of Biology R&D
RarePlex Assays are sensitive, specific, and reproducible assays for CTC detection and biomarker expression. Gain insight into the principles RareCyte applies to its assay design and validation process in this 11 minute video.


Get started with your CTC program



Contact a specialist